New research reveals that individuals who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain lost weight at a significantly accelerated pace than those who end conventional lifestyle regimens.
Findings released in a leading medical journal points out that while obese individuals can lose substantial amounts of their body weight while using the jabs, the weight is regained at an average rate of nearly a kilo each month after stopping.
"Users using these drugs must be cognizant of the danger of rapid rebound weight gain when the medication is stopped," cautioned lead investigator Dr. Susan Jebb.
This pace of recovery means a reversion to pre-treatment weight within about a year and a half.
Analyzing Therapies
The research, which reviewed dozens of trials involving thousands of participants, contrasted the results of GLP-1 agonists with other pills.
The team point out that individuals who shed pounds through diet and exercise usually experience a more gradual weight regain—around 0.1 kg a month—after stopping.
Understanding the Rapid Regain
Doctors believe the mode of action of the injections explains the heightened regain.
The injections copy a natural hormone called GLP-1, which helps regulate appetite.
"Sustained high doses of GLP-1 levels several times higher than normal may cause the body to generate a reduced amount of its endogenous GLP-1, and could lessen sensitivity to its actions," explained Dr. Adam Collins, a dietetics expert.
"Discontinuation of this medication leads to hunger is no longer kept in check, making excessive eating a significant risk."
A Lifelong Condition?
Medical guidelines recommend the injections for people with weight-linked medical conditions, alongside recommended lifestyle changes.
Many experts contend that, considering the high risk of weight regain, the treatment is often long-term.
This opinion is supported by pharmaceutical companies, who note that the findings "emphasize the chronic nature of obesity," comparing it to managing diseases like diabetes.
User Experiences
Users who have stopped the medication explain a intense resurgence of appetite.
"It felt as if a trigger that goes on and I was suddenly extremely hungry," recalled an individual.
This challenge is worsened if patients have not developed sustainable dietary or behavioural modifications during therapy.
Widespread Adoption
Recent estimates indicate that millions of people in the UK have used these injections in the past year, with demand being substantial.
- Adoption is more common among females than men.
- The middle-aged demographic shows the highest usage rates.
- Many access the medications through private healthcare rather than the NHS.
Finally, experts emphasize that while GLP-1 drugs are effective agents for weight loss, they are not a magic cure and long-term success relies on combined behavioural changes.